Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Cryogenic Solutions Inc. (CYGS) -- Ignore unavailable to you. Want to Upgrade?

To: Jeffrey S. Mitchell who wrote (3223)	8/20/1998 9:43:00 AM
From: Graham Marshman	Respond to of 4028

Jeff, The application with Hela isn't a cure for anything. All they claim to have proven is the ability to deliver a sequence specific DNA strand into the cell. If all they were testing in preclin was that ability, then that's when it could be considered complete. As for the IND - neither I nor CYGS (to the best of my knowledge) have ever subscribed to the world-rocking theory of success. They don't have a cure to initiate an IND for. They do seem to be focusing on partnerships with owners of antisense companies rather than doing it all themselves, but I imagine that's got more to do with expense than with inherent rockability. Not that most of the antisense companies have that much cash anyway. Yes, U-251 is a little different. Not one of your more common cell lines. Could be individuals background initiated, as you suggest. Could also be required for some specific potential alliance. One other company out there talking human brain tumor cells (below.) Guess we'll wait and see again. Graham RALEIGH, N.C. (Dow Jones)--Atlantic Pharmaceuticals Inc.'s (ATLC) 2-5A antisense compound that is currently under development has demonstrated an ability to inhibit the growth and survival of human cancer cells. The findings were based on both in vitro and in vivo experiments involving malignant human gliomas, a widespread and largely incurable form of brain cancer. In a press release Thursday, the biopharmaceutical company said the findings were published in the Wednesday issue of Oncogene, a peer-review journal. The company said the compound works by limiting the action of telomerase, an RNA protein complex whose expression has been implicated in cellular immortality and tumor formation. Telomerase is found in 70% to 80% of all malignant tumors, but is undetectable in most normal cells. This makes it a strong candidate for targeted anticancer therapies, such as the antisense approach presented in Oncogene, the company said.